The National Institutes of Health (NIH) Clinical Center in Bethesda, MD intends to award a sole-source contract to MaxCyte, Inc. for the purchase of a MaxCyte ExPERT GTx Electroporation Platform and associated Installation Qualification/Operational Qualification (IQ/OQ) services. This notice is for informational purposes only—no solicitation will be issued. The device is required by the Center for Cellular Engineering to replace the current Gen2 GT model, which will no longer be supported by the manufacturer beginning in mid-2026. The ExPERT GTx platform supports cGMP-compliant clinical-scale cell therapy manufacturing with non-viral delivery and compatibility with multiple cargo types. No budget amount is specified, and interested parties may submit capability statements demonstrating equivalent equipment and services.